Published in Ann Hum Genet on January 01, 2010
Atypical hemolytic uremic syndrome. Orphanet J Rare Dis (2011) 3.35
Genetics and complement in atypical HUS. Pediatr Nephrol (2010) 1.64
Atypical hemolytic uremic syndrome. Semin Nephrol (2013) 1.56
Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant (2012) 1.44
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood (2014) 1.42
Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol (2013) 1.14
Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol (2013) 1.14
Hemolytic uremic syndrome. Semin Immunopathol (2014) 1.12
Rare genetic variants in the CFI gene are associated with advanced age-related macular degeneration and commonly result in reduced serum factor I levels. Hum Mol Genet (2015) 0.95
Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol (2012) 0.84
Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol (2012) 0.83
Complement regulator CD46: genetic variants and disease associations. Hum Genomics (2015) 0.82
Review: Complement and its regulatory proteins in kidney diseases. Nephrology (Carlton) (2010) 0.82
Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res (2014) 0.79
Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol (2015) 0.79
Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol (2011) 0.78
The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies. J Thromb Haemost (2016) 0.78
Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci (2016) 0.75
Incomplete penetrance of CD46 mutation causing familial atypical hemolytic uremic syndrome. Pediatr Nephrol (2015) 0.75
Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol (2016) 0.75
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet (2006) 5.36
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med (2015) 4.78
Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol (2007) 4.59
Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. Nat Genet (2010) 3.99
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest (2003) 2.96
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet (2007) 2.79
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. Pediatr Res (2006) 2.46
Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet (2003) 2.43
Reports of large immunosuppression trials in kidney transplantation: room for improvement. Am J Transplant (2004) 2.40
Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery (2006) 2.35
Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int (2011) 2.34
Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation (2009) 2.28
Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol (2006) 2.20
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Refining esophageal cancer staging. J Thorac Cardiovasc Surg (2003) 2.18
An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood (2011) 2.16
Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant (2002) 2.10
Pheochromocytoma: presentation, diagnosis and treatment. J Hypertens (2006) 2.09
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. Radiology (2002) 1.96
Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab (2004) 1.95
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
Hyperoxaluria: a gut-kidney axis? Kidney Int (2011) 1.90
A systematic approach to managing pregnant dialysis patients--the importance of an intensified haemodiafiltration protocol. Nephrol Dial Transplant (2005) 1.87
Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients. Hum Mutat (2009) 1.85
History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol (2010) 1.84
Re-evaluating acridine orange for rapid flow cytometric enumeration of parasitemia in malaria-infected rodents. Cytometry A (2007) 1.81
Dent Disease with mutations in OCRL1. Am J Hum Genet (2004) 1.81
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Nephrocystin specifically localizes to the transition zone of renal and respiratory cilia and photoreceptor connecting cilia. J Am Soc Nephrol (2006) 1.79
An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis (2012) 1.79
Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol (2013) 1.78
Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant (2004) 1.77
Nephrocalcinosis and urolithiasis in children. Kidney Int (2011) 1.77
Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. J Med Genet (2010) 1.76
Membrane targeting and secretion of mutant uromodulin in familial juvenile hyperuricemic nephropathy. J Am Soc Nephrol (2006) 1.73
Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation (2005) 1.73
Septic complications after injection of N-butyl-2-cyanoacrylate: report of two cases and review. Gastrointest Endosc (2004) 1.70
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68
Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood (2009) 1.67
18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging (2003) 1.65
Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation (2009) 1.63
A genome-wide association study identifies LIPA as a susceptibility gene for coronary artery disease. Circ Cardiovasc Genet (2011) 1.63
C3 deposition glomerulopathy due to a functional factor H defect. Kidney Int (2008) 1.61
Hantavirus infection. J Am Soc Nephrol (2005) 1.60
Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A (2011) 1.58
p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Am J Gastroenterol (2002) 1.58
Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J (2004) 1.57
Role of clinically determined depth of tumor invasion in the treatment of esophageal carcinoma. J Thorac Cardiovasc Surg (2003) 1.57
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Clinical predictors for germline mutations in head and neck paraganglioma patients: cost reduction strategy in genetic diagnostic process as fall-out. Cancer Res (2009) 1.53
Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol (2004) 1.53
Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation (2004) 1.52
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant (2012) 1.48
Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J Invest Dermatol (2006) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation. Transplantation (2015) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Induction chemoradiotherapy increases pleural and pericardial complications after esophagectomy for cancer. J Thorac Oncol (2009) 1.47
One hundred consecutive kidney transplantations with simultaneous ipsilateral nephrectomy in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 1.47
Percutaneous endoscopic gastrostomy in children on peritoneal dialysis. Perit Dial Int (2006) 1.47
Poor interobserver agreement in the distinction of high-grade dysplasia and adenocarcinoma in pretreatment Barrett's esophagus biopsies. Am J Gastroenterol (2008) 1.46
Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int (2004) 1.46
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis (2009) 1.45
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int (2010) 1.44
Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol (2007) 1.44
No association between renin-angiotensin system gene polymorphisms and early and long-term allograft dysfunction in kidney transplant recipients. Nephrol Dial Transplant (2004) 1.43
Laparoscopic and retroperitoneoscopic treatment of pheochromocytomas and retroperitoneal paragangliomas: results of 161 tumors in 126 patients. World J Surg (2006) 1.42
The 'blood group O problem' in kidney transplantation--time to change? Nephrol Dial Transplant (2010) 1.42
Computerized patient education in kidney transplantation: testing the content validity and usability of the Organ Transplant Information System (OTIS). Patient Educ Couns (2008) 1.42
The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol Dial Transplant (2004) 1.42
Dietary hyperoxaluria is not reduced by treatment with lactic acid bacteria. J Transl Med (2013) 1.42
Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol (2011) 1.42
Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens (2008) 1.42
Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma. J Thorac Cardiovasc Surg (2003) 1.41
Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation (2010) 1.41
FTY720 mediates apoptosis-independent lymphopenia in human renal allograft recipients: different effects on CD62L+ and CCR5+ T lymphocytes. Transplantation (2004) 1.40
The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant (2003) 1.40
Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation (2005) 1.39
Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant (2008) 1.39
Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation (2011) 1.39
T2N0M0 esophageal cancer. J Thorac Cardiovasc Surg (2007) 1.38
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res (2009) 1.38